Synthetic carbohydrate antigens for HIV vaccine design

Current Opinion in Chemical Biology

Volumn 17, Issue 6, 2013, Pages 997-1005

  Wang, Lai Xi ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CARBOHYDRATE ANTIGEN; DIPHTHERIA TOXOID CRM197; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MANNOSE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ANTIGENICITY; DEFENSE MECHANISM; DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; IMMUNOGENICITY; MICROARRAY ANALYSIS; NONHUMAN; PROTEIN GLYCOSYLATION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; CARBOHYDRATE SEQUENCE; CRYSTALLOGRAPHY, X-RAY; EPITOPES; GLYCOSYLATION; HIV; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; VACCINES, SYNTHETIC;

EID: 84890196169     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.10.001     Document Type: Review

References (58)

1. Nabel G.J. Challenges and opportunities for development of an AIDS vaccine. Nature 2001, 410:1002-1007.
2. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233-236.
3. Kim J.H., Rerks-Ngarm S., Excler J.L., Michael N.L. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010, 5:428-434.
4. Kwong P.D., Mascola J.R., Nabel G.J. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Biol 2011, 3:a007278.
5. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., Kaufmann D.E., McElrath M.J., Nussenzweig M.C., Pulendran B., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12:396-407.
6. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22:358-366.
7. Walker L.M., Simek M.D., Priddy F., Gach J.S., Wagner D., Zwick M.B., Phogat S.K., Poignard P., Burton D.R. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010, 6:e1001028.
8. Lavine C.L., Lao S., Montefiori D.C., Haynes B.F., Sodroski J.G., Yang X. High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J Virol 2012, 86:2153-2164.
9. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004, 4:199-210.
10. Wang L.X. Toward oligosaccharide- and glycopeptide-based HIV vaccines. Curr Opin Drug Discov Dev 2006, 9:194-206.
11. Wang L.X. Carbohydrate-based vaccine against HIV/AIDS. Glycobiology and Drug Design. ACS Symposium Series 1102 2012, 157-186. Americal Chemical Society, Washington, DC. A.A. Klyosov (Ed.).
12. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990, 265:10373-10382.
13. Go E.P., Liao H.X., Alam S.M., Hua D., Haynes B.F., Desaire H. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J Proteome Res 2013, 12:1223-1234.
14. Zhu X., Borchers C., Bienstock R.J., Tomer K.B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 2000, 39:11194-11204.
15. Go E.P., Irungu J., Zhang Y., Dalpathado D.S., Liao H.X., Sutherland L.L., Alam S.M., Haynes B.F., Desaire H. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res 2008, 7:1660-1674.
16. Doores K.J., Bonomelli C., Harvey D.J., Vasiljevic S., Dwek R.A., Burton D.R., Crispin M., Scanlan C.N. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 2010, 107:13800-13805.
17. Raska M., Takahashi K., Czernekova L., Zachova K., Hall S., Moldoveanu Z., Elliott M.C., Wilson L., Brown R., Jancova D., et al. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 2010, 285:20860-20869.
18. Bonomelli C., Doores K.J., Dunlop D.C., Thaney V., Dwek R.A., Burton D.R., Crispin M., Scanlan C.N. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 2011, 6:e23521.
19. Reitter J.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998, 4:679-684.
20. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
21. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., Cornelissen I.L., Nottet H.S., KewalRamani V.N., Littman D.R., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
22. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
23. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002, 76:7293-7305.
24. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-2 mannose residues on the outer face of gp120. J Virol 2002, 76:7306-7321.
25. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
26. Calarese D.A., Lee H.K., Huang C.Y., Best M.D., Astronomo R.D., Stanfield R.L., Katinger H., Burton D.R., Wong C.H., Wilson I.A. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 2005, 102:13372-13377.
27. Lee H.K., Scanlan C.N., Huang C.Y., Chang A.Y., Calarese D.A., Dwek R.A., Rudd P.M., Burton D.R., Wilson I.A., Wong C.H. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed 2004, 43:1000-1003.
28. Wang L.X., Ni J., Singh S., Li H. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem Biol 2004, 11:127-134.
29. Adams E.W., Ratner D.M., Bokesch H.R., McMahon J.B., O'Keefe B.R., Seeberger P.H. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol 2004, 11:875-881.
30. Geng X., Dudkin V.Y., Mandal M., Danishefsky S.J. In pursuit of carbohydrate-based HIV vaccines, Part 2: The total synthesis of high-mannose-type gp120 fragments-evaluation of strategies directed to maximal convergence. Angew Chem Int Ed 2004, 43:2562-2565.
31. Mandal M., Dudkin V.Y., Geng X., Danishefsky S.J. In pursuit of carbohydrate-based HIV vaccines, Part 1: The total synthesis of hybrid-type gp120 fragments. Angew Chem Int Ed 2004, 43:2557-2561.
32. Dudkin V.Y., Orlova M., Geng X., Mandal M., Olson W.C., Danishefsky S.J. Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency. J Am Chem Soc 2004, 126:9560-9562.
33. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
34. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010, 84:10510-10521.
35. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
36. Amin M.N., McLellan J.S., Huang W., Orwenyo J., Burton D.R., Koff W.C., Kwong P.D., Wang L.X. Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat Chem Biol 2013, 9:521-526.
37. Pancera M., Shahzad-Ul-Hussan S., Doria-Rose N.A., McLellan J.S., Bailer R.T., Dai K., Loesgen S., Louder M.K., Staupe R.P., Yang Y., et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013, 20:804-813.
38. Julien J.P., Lee J.H., Cupo A., Murin C.D., Derking R., Hoffenberg S., Caulfield M.J., King C.R., Marozsan A.J., Klasse P.J., et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 2013, 110:4351-4356.
39. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
40. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., Stanfield R.L., Julien J.P., Ramos A., Crispin M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
41. Mouquet H., Scharf L., Euler Z., Liu Y., Eden C., Scheid J.F., Halper-Stromberg A., Gnanapragasam P.N., Spencer D.I., Seaman M.S., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 2012, 109:E3268-E3277.
42. Julien J.P., Sok D., Khayat R., Lee J.H., Doores K.J., Walker L.M., Ramos A., Diwanji D.C., Pejchal R., Cupo A., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 2013, 9:e1003342.
43. Kong L., Lee J.H., Doores K.J., Murin C.D., Julien J.P., McBride R., Liu Y., Marozsan A., Cupo A., Klasse P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013, 20:796-803.
44. Li H., Wang L.X. Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. Org Biomol Chem 2004, 2:483-488.
45. Krauss I.J., Joyce J.G., Finnefrock A.C., Song H.C., Dudkin V.Y., Geng X., Warren J.D., Chastain M., Shiver J.W., Danishefsky S.J. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody. J Am Chem Soc 2007, 129:11042-11044.
46. Wang J., Li H., Zou G., Wang L.X. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org Biomol Chem 2007, 5:1529-1540.
47. Wang S.K., Liang P.H., Astronomo R.D., Hsu T.L., Hsieh S.L., Burton D.R., Wong C.H. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A 2008, 105:3690-3695.
48. Kabanova A., Adamo R., Proietti D., Berti F., Tontini M., Rappuoli R., Costantino P. Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates. Glycoconjug J 2010, 27:501-513.
49. Marradi M., Di Gianvincenzo P., Enriquez-Navas P.M., Martinez-Avila O.M., Chiodo F., Yuste E., Angulo J., Penades S. Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12. J Mol Biol 2011, 410:798-810.
50. MacPherson I.S., Temme J.S., Habeshian S., Felczak K., Pankiewicz K., Hedstrom L., Krauss I.J. Multivalent glycocluster design through directed evolution. Angew Chem Int Ed 2011, 50:11238-11242.
51. Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations?. Nat Rev Drug Discov 2010, 9:308-324.
52. Ni J., Song H., Wang Y., Stamatos N.M., Wang L.X. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug Chem 2006, 17:493-500.
53. Joyce J.G., Krauss I.J., Song H.C., Opalka D.W., Grimm K.M., Nahas D.D., Esser M.T., Hrin R., Feng M., Dudkin V.Y., et al. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc Natl Acad Sci U S A 2008, 105:15684-15689.
54. Astronomo R.D., Lee H.K., Scanlan C.N., Pantophlet R., Huang C.Y., Wilson I.A., Blixt O., Dwek R.A., Wong C.H., Burton D.R. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 2008, 82:6359-6368.
55. Astronomo R.D., Kaltgrad E., Udit A.K., Wang S.K., Doores K.J., Huang C.Y., Pantophlet R., Paulson J.C., Wong C.H., Finn M.G., et al. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol 2010, 17:357-370.
56. Doores K.J., Fulton Z., Hong V., Patel M.K., Scanlan C.N., Wormald M.R., Finn M.G., Burton D.R., Wilson I.A., Davis B.G. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci U S A 2010, 107:17107-17112.
57. Agrawal-Gamse C., Luallen R.J., Liu B., Fu H., Lee F.H., Geng Y., Doms R.W. Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J Virol 2011, 85:470-480.
58. Aussedat B., Vohra Y., Park P.K., Fernandez-Tejada A., Alam S.M., Dennison S.M., Jaeger F.H., Anasti K., Stewart S., Blinn J.H., et al. Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J Am Chem Soc 2013, 135:13113-13120.